Pentraxin  ||| S:0 E:10 ||| NNP
3  ||| S:10 E:12 ||| CD
serum  ||| S:12 E:18 ||| CD
levels  ||| S:18 E:25 ||| NNS
in  ||| S:25 E:28 ||| IN
children  ||| S:28 E:37 ||| NNS
with  ||| S:37 E:42 ||| IN
atopic  ||| S:42 E:49 ||| FW
dermatitis  ||| S:49 E:60 ||| FW
PTX3  ||| S:60 E:65 ||| FW
behaves  ||| S:65 E:73 ||| FW
as  ||| S:73 E:76 ||| IN
an  ||| S:76 E:79 ||| DT
acute-phase  ||| S:79 E:91 ||| JJ
response  ||| S:91 E:100 ||| NN
protein  ||| S:100 E:108 ||| NN
as  ||| S:108 E:111 ||| IN
its  ||| S:111 E:115 ||| PRP$
blood  ||| S:115 E:121 ||| NN
levels  ||| S:121 E:128 ||| NNS
rapidly  ||| S:128 E:136 ||| RB
and  ||| S:136 E:140 ||| CC
dramatically  ||| S:140 E:153 ||| RB
increase  ||| S:153 E:162 ||| VB
during  ||| S:162 E:169 ||| IN
endotoxic  ||| S:169 E:179 ||| JJ
shock ||| S:179 E:184 ||| NN
,  ||| S:184 E:186 ||| ,
sepsis ||| S:186 E:192 ||| NN
,  ||| S:192 E:194 ||| ,
and  ||| S:194 E:198 ||| CC
other  ||| S:198 E:204 ||| JJ
inflammatory  ||| S:204 E:217 ||| NN
and  ||| S:217 E:221 ||| CC
infectious  ||| S:221 E:232 ||| JJ
conditions ||| S:232 E:242 ||| NNS
.  ||| S:242 E:244 ||| .
Therefore ||| S:244 E:253 ||| RB
,  ||| S:253 E:255 ||| ,
this  ||| S:255 E:260 ||| DT
study  ||| S:260 E:266 ||| NN
was  ||| S:266 E:270 ||| VBD
designed  ||| S:270 E:279 ||| VBN
to  ||| S:279 E:282 ||| TO
investigate  ||| S:282 E:294 ||| VB
a  ||| S:294 E:296 ||| DT
possible  ||| S:296 E:305 ||| JJ
role  ||| S:305 E:310 ||| NN
of  ||| S:310 E:313 ||| IN
PTX3  ||| S:313 E:318 ||| CD
in  ||| S:318 E:321 ||| IN
children  ||| S:321 E:330 ||| NNS
with  ||| S:330 E:335 ||| IN
Atopic  ||| S:335 E:342 ||| NNP
Dermatitis  ||| S:342 E:353 ||| NNP
( ||| S:353 E:354 ||| -LRB-
AD ||| S:354 E:356 ||| NNP
) ||| S:356 E:357 ||| -RRB-
.  ||| S:357 E:359 ||| .
One-hundred-and-thirty-six  ||| S:359 E:386 ||| JJ
patients  ||| S:386 E:395 ||| NNS
( ||| S:395 E:396 ||| -LRB-
37  ||| S:396 E:399 ||| CD
females ||| S:399 E:406 ||| NNS
,  ||| S:406 E:408 ||| ,
99  ||| S:408 E:411 ||| CD
males ||| S:411 E:416 ||| NNS
,  ||| S:416 E:418 ||| ,
mean  ||| S:418 E:423 ||| JJ
age  ||| S:423 E:427 ||| NN
10.4  ||| S:427 E:432 ||| CD
years ||| S:432 E:437 ||| NNS
)  ||| S:437 E:439 ||| -RRB-
were  ||| S:439 E:444 ||| VBD
enrolled  ||| S:444 E:453 ||| VBN
in  ||| S:453 E:456 ||| IN
the  ||| S:456 E:460 ||| DT
study ||| S:460 E:465 ||| NN
.  ||| S:465 E:467 ||| .
One  ||| S:467 E:471 ||| CD
hundred  ||| S:471 E:479 ||| CD
patients  ||| S:479 E:488 ||| NNS
( ||| S:488 E:489 ||| -LRB-
74 ||| S:489 E:491 ||| CD
% ||| S:491 E:492 ||| NN
)  ||| S:492 E:494 ||| -RRB-
had  ||| S:494 E:498 ||| VBD
only  ||| S:498 E:503 ||| RB
respiratory  ||| S:503 E:515 ||| JJ
symptoms  ||| S:515 E:524 ||| NNS
( ||| S:524 E:525 ||| -LRB-
allergic  ||| S:525 E:534 ||| JJ
rhinitis  ||| S:534 E:543 ||| NN
and ||| S:543 E:546 ||| CC
/ ||| S:546 E:547 ||| NNP
or  ||| S:547 E:550 ||| CC
bronchial  ||| S:550 E:560 ||| JJ
asthma ||| S:560 E:566 ||| NN
) ||| S:566 E:567 ||| -RRB-
;  ||| S:567 E:569 ||| :
thirty-six  ||| S:569 E:580 ||| JJ
patients  ||| S:580 E:589 ||| NNS
( ||| S:589 E:590 ||| -LRB-
26 ||| S:590 E:592 ||| CD
% ||| S:592 E:593 ||| NN
)  ||| S:593 E:595 ||| -RRB-
showed  ||| S:595 E:602 ||| VBD
dermatitis  ||| S:602 E:613 ||| VBN
associated  ||| S:613 E:624 ||| VBN
with  ||| S:624 E:629 ||| IN
respiratory  ||| S:629 E:641 ||| JJ
allergy  ||| S:641 E:649 ||| NN
( ||| S:649 E:650 ||| -LRB-
allergic  ||| S:650 E:659 ||| JJ
rhinitis  ||| S:659 E:668 ||| NN
and ||| S:668 E:671 ||| CC
/ ||| S:671 E:672 ||| NNP
or  ||| S:672 E:675 ||| CC
bronchial  ||| S:675 E:685 ||| JJ
asthma ||| S:685 E:691 ||| NN
) ||| S:691 E:692 ||| -RRB-
.  ||| S:692 E:694 ||| .
PTX3  ||| S:694 E:699 ||| NNP
levels  ||| S:699 E:706 ||| NNS
were  ||| S:706 E:711 ||| VBD
higher  ||| S:711 E:718 ||| JJR
in  ||| S:718 E:721 ||| IN
children  ||| S:721 E:730 ||| NNS
with  ||| S:730 E:735 ||| IN
AD  ||| S:735 E:738 ||| NNP
and  ||| S:738 E:742 ||| CC
there  ||| S:742 E:748 ||| EX
was  ||| S:748 E:752 ||| VBD
a  ||| S:752 E:754 ||| DT
significant  ||| S:754 E:766 ||| JJ
correlation  ||| S:766 E:778 ||| NN
between  ||| S:778 E:786 ||| IN
serum  ||| S:786 E:792 ||| CD
PTX3  ||| S:792 E:797 ||| CD
levels  ||| S:797 E:804 ||| NNS
and  ||| S:804 E:808 ||| CC
SCORAD  ||| S:808 E:815 ||| NNP
index  ||| S:815 E:821 ||| NN
( ||| S:821 E:822 ||| -LRB-
p-value=0.0001 ||| S:822 E:836 ||| NNP
,  ||| S:836 E:838 ||| ,
rho=0.658 ||| S:838 E:847 ||| CD
) ||| S:847 E:848 ||| -RRB-
.  ||| S:848 E:850 ||| .
Therefore ||| S:850 E:859 ||| RB
,  ||| S:859 E:861 ||| ,
this  ||| S:861 E:866 ||| DT
study  ||| S:866 E:872 ||| NN
may  ||| S:872 E:876 ||| MD
show  ||| S:876 E:881 ||| VB
that  ||| S:881 E:886 ||| IN
PTX3  ||| S:886 E:891 ||| NNP
might  ||| S:891 E:897 ||| MD
be  ||| S:897 E:900 ||| VB
a  ||| S:900 E:902 ||| DT
reliable  ||| S:902 E:911 ||| JJ
marker  ||| S:911 E:918 ||| NN
for  ||| S:918 E:922 ||| IN
the  ||| S:922 E:926 ||| DT
severity  ||| S:926 E:935 ||| NN
of  ||| S:935 E:938 ||| IN
AD  ||| S:938 E:941 ||| NNP
in  ||| S:941 E:944 ||| IN
children  ||| S:944 E:953 ||| NNS
with  ||| S:953 E:958 ||| IN
respiratory  ||| S:958 E:970 ||| JJ
allergy ||| S:970 E:977 ||| NN
.  ||| S:977 E:979 ||| .
